All Data Analysis articles
-
ReportPharma Horizons: Cell and Gene Therapy
Cell and gene therapies are transforming modern medicine, offering new hope for patients with complex and previously untreatable diseases. As innovation advances, the industry must overcome challenges in manufacturing, regulation and scalability to unlock the full potential of these groundbreaking therapies.
-
NewsBoehringer’s GLP-1 dual agonist survodutide shines in phase III trial
Survodutide could become first global glucagon/GLP-1 dual agonist, new phase III findings suggest.
-
NewsManufacturing data innovation set to accelerate medicine development
CMAC’s milestone aids the pharmaceutical industry’s transition from manual and siloed data operations to connected, intelligent manufacturing systems.
-
NewsUpcycled plastic could facilitate production of Parkinson’s drug
Bioengineered E.coli provide an eco alternative to creating L-DOPA from terephthalic acid, suggests study.
-
NewsSana's islet cell transplant therapy shows early promise in type 1 diabetes
Biotech company’s long-term data demonstrated hypoimmune (HIP)-modified islet transplantation without immunosuppression in type 1 diabetes.
-
NewsStudy optimises automated de-bagging in aseptic manufacturing
Mechanical design improvements greatly enhanced success rate during primary de-bagging for double-bag products.
-
NewsFDA revises PK study approach in new biosimilar draft guidance
Sandoz is also adjusting its global strategy by recruiting Armin Metzger as President of Biosimilar Development, Manufacturing & Supply.
-
NewsCleanroom air quality not impaired by height-adjustable furniture
Incorporating ergonomic improvements into pharmaceutical cleanrooms may not negatively impact particle contamination control, according to a new study.
-
NewsNanofiltration study highlights next-generation water treatment process
The technology could offer defect-free, high-efficiency ceramic-based water filtration through ultra-precise control of nanopores and surface structure.
-
NewsBiogen/Stoke’s zorevunersen hailed as potential first disease-modifying drug for rare epilepsy
Clinical readout for Dravet syndrome trial part of the collaboration the companies signed in 2025.
-
NewsEnhanced fluorescence technique optimises bacterial detection
Study findings could improve fluorescence-based bacterial quantification.
-
NewsNovel rapid microbiological detection method could advance surface monitoring
Innovative approach provides a promising alternative to culture-based methods for routine microbial surface monitoring.
-
NewsBlueprint’s rare disease drug Ayvakit shows long-term benefit
D816V-targeted therapy provided robust symptom control in patients with indolent systemic mastocytosis, supporting its use as a long-term treatment.
-
NewsFirst mRNA COVID-19/flu combination vaccine set for European approval
CHMP backs Moderna’s mCombriax vaccine for adults aged 50 and over.
-
ArticleApplying AI to enhance drug formulation and development
AI/ML is not replacing formulation scientists or process engineers; it is just amplifying their expertise.
-
NewsFDA drafts new ultra-rare disease therapy guidance
Agency’s planned framework is the first to support the approval process for new ultra-rare disease treatments.
-
NewsPfizer’s Braftovi improves progression-free survival in colorectal cancer
A triple therapy combination of the drug could offer a “potentially practice-changing treatment option”, according to new late-stage data.
-
NewsGSK wins dual EU approval for its ultra-long-acting biologic Exdensur
The European Commission’s decision covers the treatment’s use in severe asthma and chronic rhinosinusitis.
-
NewsAmgen wins new European approval for Uplizna in generalised myasthenia gravis
The EC decision clears a new first-in-class approach to manage the rare autoimmune condition.
-
NewsFormulation research offers step towards digital tablet design
Findings could lead to more robust tablet design and a minimising of the materials used, such as active pharmaceutical ingredients (APIs).